Please assess the completion status of the following clinical trial:

Trial Title: Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Initial Screening and Registration~* Previous diagnosis of acute lymphoblastic leukemia or brain tumor and have been off treatment and in disease-free remission for a minimum of one year; treated at the University of Minnesota Medical Center, Fairview.~* Proficient in English~* Have given informed consent (assent)~After Initial Screening~* Have evidence of attention impairment based on parent report of attention deficit (\> and = 75% on attention deficit hyperactivity disorder \[ADHD\] Index, Hyperactivity, or Cognitive-Problems/Inattention Index of parent-completed attention deficit hyperactivity disorder (ADHD) rating scale \[Conners Parent Rating Scale\] and perform at least 1.0 standard deviations below the mean on Omissions, Commissions, or Variability indexes of the Test of Variables of Attention (TOVA)~* Have an estimated Full Scale IQ score on the Wechsler Abbreviated Scale of Intelligence (WASI) \>55.~Exclusion Criteria:~* Have optic pathway gliomas and/or neurofibromatosis~* Diagnosed with ADD/ADHD prior to their cancer diagnosis~* Currently taking antidepressants or antipsychotics~* Currently being treated with stimulant medication~* Blind~* Have glaucoma~* Have a family or personal history of motor or phonic tics or Tourette syndrome~* Have seizures not controlled by antiepileptic drugs~* Taking an MAO-inhibitor~* Have a history of cardiovascular disease, uncontrolled hypertension, or hyperthyroidism, or current hypertension requiring antihypertensives

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate (Type: ACTIVE_COMPARATOR): Administered 1 capsule each day for 1 week, .3 mg/kg dose.
- Placebo (Type: PLACEBO_COMPARATOR): Administered 1 capsule each day for 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).